Acer Medical Inc. (TPEX:6857)
Taiwan · Delayed Price · Currency is TWD 95.00
-0.50 (-0.52%)
Jun 15, 2026, 10:58 AM CST
Acer Medical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 60.05 | 50.16 | 27.45 | 13.06 | 9.63 | |
Revenue Growth (YoY) | 19.73% | 82.73% | 110.17% | 35.66% | 849.41% |
Cost of Revenue | 22.55 | 18.49 | 14.56 | 6.92 | 3.19 |
Gross Profit | 37.5 | 31.67 | 12.88 | 6.14 | 6.44 |
Selling, General & Admin | 40.29 | 35.02 | 33.51 | 35.01 | 13.34 |
Research & Development | 29.94 | 26.85 | 20.54 | 26.3 | 13.63 |
Operating Expenses | 70.24 | 61.87 | 54.04 | 61.31 | 26.97 |
Operating Income | -32.73 | -30.2 | -41.16 | -55.18 | -20.53 |
Interest Expense | -0.01 | - | - | - | - |
Interest & Investment Income | 2.6 | 2.56 | 2.86 | 0.43 | 0.09 |
Currency Exchange Gain (Loss) | 0.27 | 0.04 | -0 | -0.01 | -0 |
Other Non Operating Income (Expenses) | 0.12 | 0.23 | 0.13 | 0.05 | - |
EBT Excluding Unusual Items | -29.76 | -27.36 | -38.18 | -54.71 | -20.44 |
Gain (Loss) on Sale of Assets | 0.08 | - | -0 | - | -0 |
Pretax Income | -29.69 | -27.36 | -38.18 | -54.71 | -20.45 |
Net Income | -29.69 | -27.36 | -38.18 | -54.71 | -20.45 |
Net Income to Common | -29.69 | -27.36 | -38.18 | -54.71 | -20.45 |
Shares Outstanding (Basic) | 15 | 15 | 15 | 12 | 8 |
Shares Outstanding (Diluted) | 15 | 15 | 15 | 12 | 8 |
Shares Change (YoY) | - | - | 23.43% | 59.11% | 55.06% |
EPS (Basic) | -1.95 | -1.80 | -2.51 | -4.43 | -2.64 |
EPS (Diluted) | -1.95 | -1.80 | -2.51 | -4.43 | -2.64 |
Free Cash Flow | -25.73 | -20.7 | -53.13 | -48.97 | -19.32 |
Free Cash Flow Per Share | -1.69 | -1.36 | -3.49 | -3.97 | -2.49 |
Gross Margin | 62.45% | 63.15% | 46.94% | 46.98% | 66.85% |
Operating Margin | -54.51% | -60.20% | -149.96% | -422.49% | -213.28% |
Profit Margin | -49.43% | -54.56% | -139.10% | -418.88% | -212.38% |
Free Cash Flow Margin | -42.84% | -41.27% | -193.57% | -374.94% | -200.71% |
EBITDA | -32.16 | -29.63 | -40.44 | -54.7 | -20.47 |
EBITDA Margin | -53.55% | -59.06% | -147.32% | - | -212.67% |
D&A For EBITDA | 0.58 | 0.57 | 0.72 | 0.48 | 0.06 |
EBIT | -32.73 | -30.2 | -41.16 | -55.18 | -20.53 |
EBIT Margin | -54.51% | -60.20% | -149.96% | - | -213.28% |
Advertising Expenses | - | - | - | - | 2.68 |